Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Liabilities and Shareholders Equity (2016 - 2025)

Karyopharm Therapeutics' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $108.4 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 34.06% year-over-year to $108.4 million; the TTM value through Dec 2025 reached $437.2 million, down 43.39%, while the annual FY2025 figure was $108.4 million, 34.06% down from the prior year.
  • Liabilities and Shareholders Equity reached $108.4 million in Q4 2025 per KPTI's latest filing, up from $96.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $358.2 million in Q4 2022 to a low of $96.2 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $230.2 million, with a median of $247.3 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: rose 17.32% in 2022, then tumbled 50.99% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $305.3 million in 2021, then rose by 17.32% to $358.2 million in 2022, then plummeted by 32.87% to $240.4 million in 2023, then crashed by 31.62% to $164.4 million in 2024, then tumbled by 34.06% to $108.4 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Liabilities and Shareholders Equity are $108.4 million (Q4 2025), $96.2 million (Q3 2025), and $104.9 million (Q2 2025).